Media stories about Prima BioMed (NASDAQ:PBMD) have trended positive on Thursday, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Prima BioMed earned a news sentiment score of 0.27 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.6051761222997 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Separately, Maxim Group reiterated a “buy” rating and set a $7.00 price target on shares of Prima BioMed in a report on Thursday, November 9th.

Shares of Prima BioMed (NASDAQ PBMD) traded down $0.02 during mid-day trading on Thursday, hitting $1.70. The stock had a trading volume of 28,810 shares, compared to its average volume of 82,151. Prima BioMed has a twelve month low of $1.40 and a twelve month high of $3.26. The company has a current ratio of 6.06, a quick ratio of 6.06 and a debt-to-equity ratio of 0.22.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2017/11/30/prima-biomed-pbmd-receives-coverage-optimism-rating-of-0-27.html.

About Prima BioMed

Prima BioMed Ltd is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.

Insider Buying and Selling by Quarter for Prima BioMed (NASDAQ:PBMD)

Receive News & Ratings for Prima BioMed Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd and related companies with MarketBeat.com's FREE daily email newsletter.